kynurenine has been researched along with Neoplasms in 99 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
" In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases." | 9.01 | Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019) |
"Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)." | 6.66 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020) |
"In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin." | 6.38 | Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991) |
" In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases." | 5.01 | Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019) |
"Tryptophan metabolism is critical for cell proliferation, inflammation and immunoregulation." | 4.91 | The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. ( Becker, K; Fuchs, D; Gostner, JM; Überall, F, 2015) |
"Alterations of these enzymes in cancers can shift the balance and lead to an increased production of specific byproducts that can function as oncometabolites." | 3.01 | Tryptophan and its metabolites in normal physiology and cancer etiology. ( Barnes, S; Conacci-Sorrell, M; Garcia, R; Perez-Castro, L; Venkateswaran, N, 2023) |
"Upregulation of IDO1 correlates with cancer aggression, poor prognosis and shortened patient survival." | 3.01 | Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated. ( Charehjoo, A; Majidpoor, J; Mortezaee, K, 2023) |
" This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizumab in Japanese patients with advanced solid tumours." | 2.94 | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. ( Ebata, T; Fujiwara, Y; Inatani, M; Iwasa, S; Kitano, S; Kondo, S; Koyama, T; Nakai, K; Sato, N; Shimizu, T; Shimomura, A; Tamura, K; Yamamoto, N; Yonemori, K, 2020) |
"Kynurenine promotes T Reg (regulatory) differentiation, which leads to increased production of anti-inflammatory cytokines and suppression of cytotoxic activity of T cells." | 2.72 | The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. ( Ala, M, 2021) |
"The development of drug resistance in tumors is a major obstacle to effective cancer chemotherapy and represents one of the most significant complications to improving long-term patient outcomes." | 2.72 | Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. ( Feun, LG; Nguyen, DJM; Savaraj, N; Spector, SA; Theodoropoulos, G; Wangpaichitr, M; Wu, C, 2021) |
"Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)." | 2.66 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020) |
"Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)-programmed death-ligand 1 signaling pathways." | 2.61 | Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. ( Bao, R; Labadie, BW; Luke, JJ, 2019) |
"However, without Trp, tumors cannot achieve an immune escape through either enzyme." | 2.58 | Targeting tryptophan availability to tumors: the answer to immune escape? ( Badawy, AA, 2018) |
"A series of human cancers over-express IDO1 in a constitutive way." | 2.55 | IDO1: An important immunotherapy target in cancer treatment. ( Li, F; Li, S; Liu, J; Zhang, R, 2017) |
"In the field of psychiatric disorders, namely in schizophrenia and depression, the role of IDO is linked to immune dysregulation." | 2.52 | [Indoleamine 2,3-dioxygenase in oncology and psychiatry]. ( Horáček, J; Vonka, V, 2015) |
"IDO can be expressed by tumors themselves, but, in addition, its natural site of expression is the host immune cells recruited by the tumor (particularly dendritic cells and macrophages)." | 2.48 | Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. ( Johnson, TS; Munn, DH, 2012) |
"In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin." | 2.38 | Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991) |
"Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes." | 1.91 | L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes. ( Abooali, M; Berger, SM; Cholewa, D; Fasler-Kan, E; Gibbs, BF; Klenova, E; Lall, GS; Milošević, M; Ruggiero, S; Schlichtner, S; Sumbayev, VV; Yasinska, IM, 2023) |
"Tumors are heterogeneous cellular environments with entwined metabolic dependencies." | 1.72 | A pan-cancer metabolic atlas of the tumor microenvironment. ( Baruah, P; Ghoshdastider, U; Kulshrestha, T; Rohatgi, N; Skanderup, AJ, 2022) |
"Discovery of novel strategies for cancer immunotherapy including natural small molecules is needed." | 1.72 | Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. ( Cao, Z; Chen, C; Chen, G; Huang, J; Huang, M; Lei, H; Lu, Y; Ma, Y; Song, Y; Wu, F; Zhang, C; Zhang, L; Zhao, Y; Zhou, J, 2022) |
"Multidrug resistant cancer cells are hard to eradicate for the inefficacy of conventional anticancer drugs." | 1.42 | An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. ( Buondonno, I; Campia, I; Castella, B; Gazzano, E; Ghigo, D; Kopecka, J; Riganti, C; Rolando, B, 2015) |
"A total of 971 incident cancer cases (507 men and 464 women) were identified over a median follow-up time of 12 years." | 1.40 | Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. ( Eussen, SJ; Meyer, K; Midttun, Ø; Nygård, O; Tell, GS; Ueland, PM; Ulvik, A; Vollset, SE; Zuo, H, 2014) |
"Malignant tumors arise, in part, because the immune system does not adequately recognize and destroy them." | 1.36 | Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. ( Bowman, KJ; Burn, TC; Combs, AP; Fridman, JS; Haley, PJ; Hansbury, MJ; Koblish, HK; Neilan, CL; Scherle, PA; Sparks, RB; Vaddi, K; Waeltz, P; Yang, G; Yue, EW, 2010) |
"If bladder cancer is caused by agents present in the urine, as is widely believed, this mechanism may also protect against carcinogenesis." | 1.27 | Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis. ( Anderson, K; Kaufman, JE; Parsons, CL, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 16 (16.16) | 18.7374 |
1990's | 1 (1.01) | 18.2507 |
2000's | 6 (6.06) | 29.6817 |
2010's | 35 (35.35) | 24.3611 |
2020's | 41 (41.41) | 2.80 |
Authors | Studies |
---|---|
Lin, R | 1 |
Elf, S | 1 |
Shan, C | 1 |
Kang, HB | 1 |
Ji, Q | 1 |
Zhou, L | 2 |
Hitosugi, T | 1 |
Zhang, L | 3 |
Zhang, S | 2 |
Seo, JH | 1 |
Xie, J | 1 |
Tucker, M | 1 |
Gu, TL | 1 |
Sudderth, J | 1 |
Jiang, L | 1 |
Mitsche, M | 1 |
DeBerardinis, RJ | 1 |
Wu, S | 1 |
Li, Y | 2 |
Mao, H | 1 |
Chen, PR | 1 |
Wang, D | 2 |
Chen, GZ | 1 |
Hurwitz, SJ | 1 |
Lonial, S | 1 |
Arellano, ML | 1 |
Khoury, HJ | 1 |
Khuri, FR | 1 |
Lee, BH | 1 |
Lei, Q | 1 |
Brat, DJ | 1 |
Ye, K | 1 |
Boggon, TJ | 1 |
He, C | 1 |
Kang, S | 1 |
Fan, J | 1 |
Chen, J | 2 |
Yang, C | 1 |
Ng, CT | 1 |
Li, D | 1 |
Perez-Castro, L | 1 |
Garcia, R | 1 |
Venkateswaran, N | 1 |
Barnes, S | 1 |
Conacci-Sorrell, M | 1 |
Watson, MJ | 1 |
Delgoffe, GM | 1 |
Peyraud, F | 1 |
Guegan, JP | 1 |
Bodet, D | 1 |
Cousin, S | 1 |
Bessede, A | 1 |
Italiano, A | 1 |
Fiore, A | 1 |
Zeitler, L | 2 |
Russier, M | 1 |
Groß, A | 1 |
Hiller, MK | 1 |
Parker, JL | 1 |
Stier, L | 1 |
Köcher, T | 1 |
Newstead, S | 1 |
Murray, PJ | 2 |
Rohatgi, N | 1 |
Ghoshdastider, U | 1 |
Baruah, P | 1 |
Kulshrestha, T | 1 |
Skanderup, AJ | 1 |
McGovern, K | 3 |
Castro, AC | 2 |
Cavanaugh, J | 2 |
Coma, S | 2 |
Walsh, M | 1 |
Tchaicha, J | 2 |
Syed, S | 1 |
Natarajan, P | 1 |
Manfredi, M | 2 |
Zhang, XM | 2 |
Ecsedy, J | 1 |
Wang, LT | 1 |
Liu, KY | 1 |
Wang, SN | 1 |
Lin, MH | 1 |
Liao, YM | 1 |
Lin, PC | 1 |
Huang, SK | 1 |
Hsu, SH | 1 |
Chiou, SS | 1 |
Zhang, Y | 3 |
Hu, Z | 1 |
Zhang, J | 1 |
Ren, C | 1 |
Wang, Y | 1 |
Chen, G | 1 |
Huang, J | 1 |
Lei, H | 1 |
Wu, F | 1 |
Chen, C | 1 |
Song, Y | 1 |
Cao, Z | 1 |
Zhang, C | 2 |
Ma, Y | 1 |
Huang, M | 1 |
Zhou, J | 1 |
Lu, Y | 1 |
Zhao, Y | 1 |
Cui, J | 1 |
Tian, Y | 1 |
Liu, T | 2 |
Lin, X | 1 |
Li, L | 2 |
Li, Z | 1 |
Shen, L | 1 |
Powderly, JD | 1 |
Klempner, SJ | 1 |
Naing, A | 1 |
Bendell, J | 1 |
Garrido-Laguna, I | 1 |
Catenacci, DVT | 1 |
Taylor, MH | 1 |
Lee, JJ | 1 |
Zheng, F | 1 |
Zhou, F | 1 |
Gong, X | 1 |
Gowda, H | 1 |
Beatty, GL | 1 |
Zhou, H | 1 |
Wen, H | 1 |
Wang, L | 1 |
Xu, M | 1 |
Jia, Y | 1 |
Duan, S | 1 |
Di, B | 1 |
Yu, Z | 1 |
Hu, C | 1 |
Charehjoo, A | 1 |
Majidpoor, J | 1 |
Mortezaee, K | 1 |
Azimnasab-Sorkhabi, P | 1 |
Soltani-Asl, M | 1 |
Yoshinaga, TT | 1 |
Zaidan Dagli, ML | 1 |
Massoco, CO | 1 |
Kfoury Junior, JR | 1 |
Xue, C | 1 |
Li, G | 1 |
Zheng, Q | 1 |
Gu, X | 1 |
Shi, Q | 1 |
Su, Y | 1 |
Chu, Q | 1 |
Yuan, X | 1 |
Bao, Z | 1 |
Lu, J | 2 |
Schlichtner, S | 1 |
Yasinska, IM | 1 |
Klenova, E | 1 |
Abooali, M | 1 |
Lall, GS | 1 |
Berger, SM | 1 |
Ruggiero, S | 1 |
Cholewa, D | 1 |
Milošević, M | 1 |
Gibbs, BF | 1 |
Fasler-Kan, E | 1 |
Sumbayev, VV | 1 |
Kim, HJ | 1 |
Moon, JH | 1 |
Chung, SW | 1 |
Abraham, I | 1 |
Park, J | 1 |
Nah, Y | 1 |
Kim, WJ | 1 |
Wu, D | 1 |
Zhou, Y | 1 |
Fu, H | 1 |
Huang, Q | 1 |
Qin, G | 1 |
Lv, J | 2 |
Lai, S | 1 |
Zhang, H | 2 |
Tang, K | 2 |
Ma, J | 2 |
Fiskesund, R | 1 |
Zhang, X | 1 |
Huang, B | 2 |
Holthuijsen, DDB | 1 |
van Roekel, EH | 1 |
Bours, MJL | 1 |
Ueland, PM | 3 |
Breukink, SO | 1 |
Janssen-Heijnen, MLG | 1 |
Keulen, ETP | 1 |
Gsur, A | 1 |
Kok, DE | 1 |
Ulvik, A | 3 |
Weijenberg, MP | 1 |
Eussen, SJPM | 1 |
Günther, J | 1 |
Däbritz, J | 1 |
Wirthgen, E | 2 |
Thomas, S | 1 |
Laury-Kleintop, L | 1 |
Prendergast, GC | 1 |
Zhai, L | 1 |
Ladomersky, E | 1 |
Bell, A | 1 |
Dussold, C | 1 |
Cardoza, K | 1 |
Qian, J | 1 |
Lauing, KL | 1 |
Wainwright, DA | 2 |
Klar, R | 1 |
Michel, S | 1 |
Schell, M | 1 |
Hinterwimmer, L | 1 |
Zippelius, A | 1 |
Jaschinski, F | 1 |
Opitz, CA | 1 |
Somarribas Patterson, LF | 1 |
Mohapatra, SR | 1 |
Dewi, DL | 1 |
Sadik, A | 1 |
Platten, M | 2 |
Trump, S | 1 |
Sadok, I | 1 |
Tyszczuk-Rotko, K | 1 |
Mroczka, R | 1 |
Staniszewska, M | 1 |
Hua, S | 1 |
Chen, F | 1 |
Wang, X | 1 |
Gou, S | 1 |
Riess, C | 1 |
Schneider, B | 1 |
Kehnscherper, H | 1 |
Gesche, J | 1 |
Irmscher, N | 1 |
Shokraie, F | 1 |
Classen, CF | 1 |
Domanska, G | 1 |
Zimpfer, A | 1 |
Strüder, D | 1 |
Junghanss, C | 1 |
Maletzki, C | 1 |
Lanser, L | 1 |
Kink, P | 1 |
Egger, EM | 1 |
Willenbacher, W | 1 |
Fuchs, D | 4 |
Weiss, G | 2 |
Kurz, K | 1 |
Park, SY | 1 |
Nam, JS | 1 |
Jiang, S | 1 |
Li, H | 3 |
Piao, L | 1 |
Jin, Z | 1 |
Liu, J | 2 |
Chen, S | 1 |
Liu, LL | 1 |
Shao, Y | 1 |
Zhong, S | 1 |
Wu, B | 1 |
Li, W | 1 |
Ren, J | 1 |
Wang, H | 1 |
Jin, R | 1 |
Heinsberg, LW | 1 |
Lockwood, MB | 1 |
Jang, MK | 1 |
Doorenbos, AZ | 1 |
Campesato, LF | 1 |
Budhu, S | 1 |
Weng, CH | 1 |
Gigoux, M | 1 |
Cohen, IJ | 1 |
Redmond, D | 1 |
Mangarin, L | 1 |
Pourpe, S | 1 |
Liu, C | 1 |
Zappasodi, R | 1 |
Zamarin, D | 1 |
Manfredi, MG | 1 |
Merghoub, T | 1 |
Wolchok, JD | 1 |
Boros, F | 1 |
Vécsei, L | 1 |
Le Naour, J | 1 |
Galluzzi, L | 1 |
Zitvogel, L | 1 |
Kroemer, G | 1 |
Vacchelli, E | 1 |
Heidari, F | 1 |
Ramezani, A | 1 |
Erfani, N | 1 |
Razmkhah, M | 1 |
Liu, XH | 1 |
Zhai, XY | 1 |
Ala, M | 1 |
Kim, M | 1 |
Tomek, P | 1 |
Matsuda, A | 1 |
Hata, A | 1 |
Tanaka, A | 1 |
Matsuda, H | 1 |
Wangpaichitr, M | 1 |
Theodoropoulos, G | 1 |
Nguyen, DJM | 1 |
Wu, C | 1 |
Spector, SA | 1 |
Feun, LG | 1 |
Savaraj, N | 1 |
Li, F | 1 |
Zhang, R | 1 |
Li, S | 1 |
Liu, Y | 1 |
Liang, X | 1 |
Yin, X | 1 |
Ji, T | 1 |
Dong, W | 1 |
Jin, X | 1 |
Chen, D | 1 |
Xie, HQ | 1 |
Zhao, B | 1 |
Zhao, T | 1 |
Hu, ZW | 1 |
Cao, X | 1 |
Qin, FX | 1 |
Ait-Belkacem, R | 2 |
Bol, V | 1 |
Hamm, G | 1 |
Schramme, F | 1 |
Van Den Eynde, B | 1 |
Poncelet, L | 2 |
Pamelard, F | 1 |
Stauber, J | 2 |
Gomes, B | 2 |
Schäuble, S | 1 |
Stavrum, AK | 1 |
Bockwoldt, M | 1 |
Puntervoll, P | 1 |
Heiland, I | 1 |
Cervenka, I | 1 |
Agudelo, LZ | 1 |
Ruas, JL | 1 |
Cheong, JE | 1 |
Sun, L | 1 |
Badawy, AA | 1 |
Triplett, TA | 1 |
Garrison, KC | 1 |
Marshall, N | 1 |
Donkor, M | 1 |
Blazeck, J | 1 |
Lamb, C | 1 |
Qerqez, A | 1 |
Dekker, JD | 1 |
Tanno, Y | 1 |
Lu, WC | 1 |
Karamitros, CS | 1 |
Ford, K | 1 |
Tan, B | 1 |
Kumada, Y | 1 |
Yamany, MS | 1 |
Sentandreu, E | 1 |
Fromm, G | 1 |
Tiziani, S | 1 |
Schreiber, TH | 1 |
Ehrlich, LIR | 1 |
Stone, E | 1 |
Georgiou, G | 1 |
Wang, W | 1 |
Zhuang, X | 1 |
Liu, W | 1 |
Dong, L | 1 |
Sun, H | 1 |
Du, G | 1 |
Ye, L | 1 |
Labadie, BW | 1 |
Bao, R | 1 |
Luke, JJ | 1 |
Cronin, SJF | 1 |
Seehus, C | 1 |
Weidinger, A | 1 |
Talbot, S | 1 |
Reissig, S | 1 |
Seifert, M | 1 |
Pierson, Y | 1 |
McNeill, E | 1 |
Longhi, MS | 1 |
Turnes, BL | 1 |
Kreslavsky, T | 1 |
Kogler, M | 1 |
Hoffmann, D | 1 |
Ticevic, M | 1 |
da Luz Scheffer, D | 1 |
Tortola, L | 1 |
Cikes, D | 1 |
Jais, A | 1 |
Rangachari, M | 1 |
Rao, S | 1 |
Paolino, M | 1 |
Novatchkova, M | 1 |
Aichinger, M | 1 |
Barrett, L | 1 |
Latremoliere, A | 1 |
Wirnsberger, G | 1 |
Lametschwandtner, G | 1 |
Busslinger, M | 1 |
Zicha, S | 1 |
Latini, A | 1 |
Robson, SC | 1 |
Waisman, A | 1 |
Andrews, N | 1 |
Costigan, M | 1 |
Channon, KM | 1 |
Kozlov, AV | 1 |
Tebbe, M | 1 |
Johnsson, K | 1 |
Woolf, CJ | 1 |
Penninger, JM | 1 |
Sforzini, L | 1 |
Nettis, MA | 1 |
Mondelli, V | 1 |
Pariante, CM | 1 |
Marillier, R | 1 |
Zimmer, P | 1 |
Joisten, N | 1 |
Schenk, A | 1 |
Bloch, W | 1 |
Ning, S | 1 |
Ghandi, M | 1 |
Kryukov, GV | 1 |
Gopal, S | 1 |
Deik, A | 1 |
Souza, A | 1 |
Pierce, K | 1 |
Keskula, P | 1 |
Hernandez, D | 1 |
Ann, J | 1 |
Shkoza, D | 1 |
Apfel, V | 1 |
Zou, Y | 1 |
Vazquez, F | 1 |
Barretina, J | 1 |
Pagliarini, RA | 1 |
Galli, GG | 1 |
Root, DE | 1 |
Hahn, WC | 1 |
Tsherniak, A | 1 |
Giannakis, M | 1 |
Schreiber, SL | 1 |
Clish, CB | 1 |
Garraway, LA | 1 |
Sellers, WR | 1 |
Ebata, T | 1 |
Shimizu, T | 1 |
Fujiwara, Y | 1 |
Tamura, K | 1 |
Kondo, S | 1 |
Iwasa, S | 1 |
Yonemori, K | 1 |
Shimomura, A | 1 |
Kitano, S | 1 |
Koyama, T | 1 |
Sato, N | 1 |
Nakai, K | 1 |
Inatani, M | 1 |
Yamamoto, N | 1 |
Wick, W | 1 |
Opitz, C | 1 |
Zuo, H | 2 |
Tell, GS | 2 |
Vollset, SE | 2 |
Nygård, O | 2 |
Midttun, Ø | 2 |
Meyer, K | 2 |
Eussen, SJ | 2 |
Gostner, JM | 1 |
Becker, K | 1 |
Überall, F | 1 |
Campia, I | 1 |
Buondonno, I | 1 |
Castella, B | 1 |
Rolando, B | 1 |
Kopecka, J | 1 |
Gazzano, E | 1 |
Ghigo, D | 1 |
Riganti, C | 1 |
Vonka, V | 1 |
Horáček, J | 1 |
Yeung, AW | 1 |
Terentis, AC | 1 |
King, NJ | 1 |
Thomas, SR | 1 |
Weinmann, H | 1 |
Bostian, AC | 1 |
Eoff, RL | 1 |
Karami, P | 1 |
Majidi, MR | 1 |
Johari-Ahar, M | 1 |
Barar, J | 1 |
Omidi, Y | 1 |
Shi, JG | 1 |
Bowman, KJ | 2 |
Chen, X | 1 |
Maleski, J | 1 |
Leopold, L | 1 |
Yeleswaram, S | 1 |
Macchiarulo, A | 1 |
Camaioni, E | 1 |
Nuti, R | 1 |
Pellicciari, R | 1 |
Costantino, G | 1 |
Koblish, HK | 1 |
Hansbury, MJ | 1 |
Yang, G | 1 |
Neilan, CL | 1 |
Haley, PJ | 1 |
Burn, TC | 1 |
Waeltz, P | 1 |
Sparks, RB | 1 |
Yue, EW | 1 |
Combs, AP | 1 |
Scherle, PA | 1 |
Vaddi, K | 1 |
Fridman, JS | 1 |
Munn, DH | 2 |
Garber, K | 1 |
Harden, JL | 1 |
Egilmez, NK | 1 |
Johnson, TS | 1 |
SPACEK, M | 1 |
QUAGLIARIELLO, E | 1 |
AURICCHIO, S | 1 |
CASALE, M | 1 |
TANCREDI, F | 1 |
LEPPANEN, VV | 1 |
OKA, M | 1 |
NAIK, VR | 1 |
BHIDE, SV | 1 |
TAKATORI, K | 1 |
ISHIGURO, I | 1 |
ASANO, S | 1 |
KUZUYA, H | 1 |
OKAMOTO, M | 1 |
KONO, R | 1 |
MORISHIMA, K | 1 |
SHIBA, S | 1 |
TERAWAKI, A | 1 |
MIYATAKE, M | 1 |
PERISSINOTTO, B | 1 |
BENASSI, CA | 1 |
ALLEGRI, G | 1 |
BRYAN, GT | 1 |
BROWN, RR | 4 |
PRICE, JM | 1 |
KHALAFALLAH, AS | 1 |
ABUL-FADL, MA | 1 |
HAGGERTY, JF | 1 |
SULLIVAN, MX | 1 |
Schröcksnadel, K | 1 |
Wirleitner, B | 1 |
Winkler, C | 2 |
Schroecksnadel, K | 1 |
Fiegl, M | 1 |
Prassl, K | 1 |
Denz, HA | 1 |
Khan, JA | 1 |
Forouhar, F | 1 |
Tao, X | 1 |
Tong, L | 1 |
Zamanakou, M | 1 |
Germenis, AE | 1 |
Karanikas, V | 1 |
Ogasawara, K | 1 |
Nakamura, Y | 1 |
Nakamura, J | 1 |
Yokoyama, K | 1 |
Ozaki, Y | 1 |
Datta, SP | 1 |
Borden, EC | 2 |
Sondel, PM | 2 |
Malone, DG | 1 |
Kaufman, JE | 1 |
Anderson, K | 1 |
Parsons, CL | 1 |
Lee, CM | 2 |
Kohler, PC | 1 |
Hank, JA | 1 |
Storer, BE | 1 |
Byrne, GI | 1 |
Lehmann, LK | 1 |
Kirschbaum, JG | 1 |
Coon, WW | 1 |
Nagler, E | 1 |
Cozzolino, G | 1 |
Scianaro, L | 1 |
Dominici, G | 1 |
Milia, U | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)[NCT03085914] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878] | 20 participants (Anticipated) | Interventional | 2023-07-10 | Enrolling by invitation | |||
The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure[NCT02967419] | 60 participants (Anticipated) | Observational | 2017-01-31 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A DLT was defined as the occurrence of any of the protocol-specified toxicities occurring up to and including Day 28 for the cohorts where mFOLFOX6 and nab-paclitaxel/gemcitabine are administered and Day 21 for all other chemotherapy regimens in Phase 1, except those with a clear alternative explanation (eg, disease progression) or transient (≤ 72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. (NCT03085914)
Timeframe: 28 days
Intervention | Participants (Count of Participants) |
---|---|
Group A: Epa + Pembrolizumab + mFOLFOX6 | 2 |
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 0 |
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 0 |
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 0 |
Group E: Epa + Pembrolizumab + Cyclophosphamide | 0 |
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 3 |
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 0 |
A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of epacadostat, pembrolizumab, or chemotherapy. Serious adverse event is defined as an event that meets 1 of the following criteria: is fatal or life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or a substantial disruption of a person's ability to conduct normal life functions, constitutes a congenital anomaly or birth defect,is a medically important event that may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the outcomes listed above. (NCT03085914)
Timeframe: Up to 21 months
Intervention | Participants (Count of Participants) | |
---|---|---|
TEAE | Serious TEAE | |
Group A: Epa + Pembrolizumab + mFOLFOX6 | 9 | 5 |
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 9 | 5 |
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 11 | 3 |
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 9 | 6 |
Group E: Epa + Pembrolizumab + Cyclophosphamide | 13 | 4 |
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 8 | 6 |
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 11 | 5 |
ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. (NCT03085914)
Timeframe: Up to Week 18
Intervention | Participants (Count of Participants) | |
---|---|---|
Complete Response | Partial Response | |
Group A: Epa + Pembrolizumab + mFOLFOX6 | 0 | 5 |
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 1 | 2 |
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 0 | 3 |
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 0 | 2 |
Group E: Epa + Pembrolizumab + Cyclophosphamide | 0 | 3 |
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 0 | 1 |
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 0 | 5 |
40 reviews available for kynurenine and Neoplasms
Article | Year |
---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Gene Expression Regulation, Enzymologic; Huma | 2021 |
Tryptophan and its metabolites in normal physiology and cancer etiology.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptophan; Tryp | 2023 |
Fighting in a wasteland: deleterious metabolites and antitumor immunity.
Topics: Adenosine; Animals; Humans; Immunotherapy; Kynurenine; Lactic Acid; Neoplasms; Reactive Oxygen Speci | 2022 |
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; | 2022 |
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm | 2022 |
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Topics: Ecosystem; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Mi | 2023 |
IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidoreductases; Tryptophan; Tu | 2023 |
Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Microenvironm | 2023 |
Tryptophan metabolism in health and disease.
Topics: Dioxygenases; Humans; Kynurenine; Neoplasms; Tryptophan | 2023 |
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment.
Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm | 2019 |
The therapeutic potential of targeting tryptophan catabolism in cancer.
Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; | 2020 |
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer.
Topics: Anemia; Animals; Depression; Fatigue; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Ky | 2020 |
Systematic Review of the Kynurenine Pathway and Psychoneurological Symptoms Among Adult Cancer Survivors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cancer Survivors; Female; Humans; Kynurenic Acid; Kynure | 2020 |
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Drug Development; Humans; Kynurenine; Neoplasms | 2020 |
Trial watch: IDO inhibitors in cancer therapy.
Topics: Animals; Enzyme Inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan | 2020 |
Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Topics: Adjuvants, Immunologic; Humans; Immune System Diseases; Immunologic Factors; Indoleamine-Pyrrole 2,3 | 2022 |
Role of tryptophan metabolism in cancers and therapeutic implications.
Topics: Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm Proteins; Neopl | 2021 |
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2021 |
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Immunotherapy; Indolea | 2021 |
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
Topics: Cisplatin; Drug Resistance, Neoplasm; Energy Metabolism; Glycolysis; Humans; Kynurenine; Mitochondri | 2021 |
IDO1: An important immunotherapy target in cancer treatment.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immu | 2017 |
Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health.
Topics: Brain; Depression; Exercise; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Inflammati | 2017 |
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Topics: Animals; Antineoplastic Agents; Humans; Immunosuppressive Agents; Immunotherapy; Indoleamine-Pyrrole | 2018 |
Targeting tryptophan availability to tumors: the answer to immune escape?
Topics: Albumins; Animals; Biomarkers; Fatty Acids; Humans; Kynurenine; Metabolic Networks and Pathways; Mol | 2018 |
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Topics: Cell Line, Tumor; Computational Biology; Enzyme Inhibitors; Gene Expression Profiling; Humans; Immun | 2019 |
Inflammation in cancer and depression: a starring role for the kynurenine pathway.
Topics: Antidepressive Agents; Depression; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infl | 2019 |
[Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases].
Topics: Animals; Autoimmune Diseases; Brain; Dietary Supplements; Disease Models, Animal; Dose-Response Rela | 2013 |
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Topics: Animals; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellular; Immunotherapy; Indoleamine | 2015 |
[Indoleamine 2,3-dioxygenase in oncology and psychiatry].
Topics: Brain; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Kynurenine; Mental Disorders; | 2015 |
Role of indoleamine 2,3-dioxygenase in health and disease.
Topics: Animals; Bacterial Infections; Catalysis; Gene Expression Regulation, Enzymologic; Humans; Indoleami | 2015 |
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.
Topics: Adenosine; Humans; Immunotherapy; Kynurenine; Neoplasms; Protein Serine-Threonine Kinases; Receptor, | 2016 |
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Topics: Animals; Crystallography, X-Ray; Enzyme Activation; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2 | 2009 |
New promises for manipulation of kynurenine pathway in cancer and neurological diseases.
Topics: Animals; Drug Delivery Systems; Drug Discovery; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3, | 2009 |
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.
Topics: Animals; Autoimmunity; Cell Lineage; Dendritic Cells; Gene Expression Regulation; Humans; Immune Tol | 2012 |
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Topics: Animals; Antineoplastic Agents; Dendritic Cells; Enzyme Inhibitors; Humans; Immune Tolerance; Indole | 2012 |
Monitoring tryptophan metabolism in chronic immune activation.
Topics: Autoimmune Diseases; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infections; Kynurenine; Neoplasms | 2006 |
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Topics: Acrylamides; Adenosine Diphosphate Ribose; Aging; Animals; Antineoplastic Agents; Autoimmune Disease | 2007 |
Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Topics: Animals; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptop | 2007 |
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Autoimmune Diseases; Enzyme Induction; Female; Humans; Indoleami | 1991 |
3 trials available for kynurenine and Neoplasms
Article | Year |
---|---|
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Kynurenine; Neoplasms; Programmed Cell Death | 2022 |
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl | 2020 |
Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Topics: Adult; Aged; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Male; Middle Aged; Mo | 2017 |
56 other studies available for kynurenine and Neoplasms
Article | Year |
---|---|
Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling.
Topics: Amino Acid Transport System y+; Ferroptosis; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenin | 2022 |
A pan-cancer metabolic atlas of the tumor microenvironment.
Topics: Cell Line, Tumor; Humans; Kynurenine; Neoplasms; Stromal Cells; Tryptophan Oxygenase; Tumor Microenv | 2022 |
Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression.
Topics: Animals; Cytochrome P-450 CYP1A1; Cytokines; Humans; Immunosuppression Therapy; Kynurenine; Mice; Ne | 2022 |
Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL.
Topics: Animals; Humans; Kynurenine; Mice; Neoplasms; Polycyclic Aromatic Hydrocarbons; Receptors, Aryl Hydr | 2023 |
Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape.
Topics: Animals; Cell Line, Tumor; Flavones; Immunotherapy; Kynurenine; Mice; Neoplasms; Programmed Cell Dea | 2022 |
Pancancer Analysis of Revealed
Topics: B7 Antigens; Biomarkers, Tumor; DNA; Humans; Immunotherapy; Kynurenine; Methyltransferases; Microsat | 2022 |
Label-free tumor cell screening based on IDO1-mediated tryptophan metabolism at single cell level.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidation-Reduction; Tryptophan | 2022 |
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes.
Topics: Humans; Immune Evasion; Kynurenine; Neoplasms; Signal Transduction; T-Lymphocytes; Tumor Microenviro | 2023 |
The role of cytokines and Indolamine-2.3 dioxygenase in experiencing a psycho-neurological symptom cluster in hematological cancer patients: IL-1alpha, IL-1beta, IL-4, IL-6, TNF-alpha, kynurenine, and tryptophan.
Topics: Cytokines; Dioxygenases; Hematologic Neoplasms; Humans; Interleukin-4; Interleukin-6; Kynurenine; Ne | 2023 |
IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy.
Topics: Drug Delivery Systems; Humans; Immunotherapy; Kynurenine; Micelles; Neoplasms; Tryptophan; Tumor Mic | 2023 |
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1.
Topics: Animals; Bias; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Erythroid Precursor Cells; | 2023 |
Longitudinal associations of macronutrient and micronutrient intake with plasma kynurenines in colorectal cancer survivors up to 12 months posttreatment.
Topics: Eating; Humans; Kynurenic Acid; Kynurenine; Micronutrients; Neoplasms; Nutrients; Prospective Studie | 2023 |
Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues.
Topics: Animals; Antibodies, Monoclonal; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluoresc | 2019 |
Quantification of IDO1 enzyme activity in normal and malignant tissues.
Topics: Animals; Enzyme Assays; HeLa Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; | 2019 |
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Screening As | 2020 |
Simultaneous voltammetric analysis of tryptophan and kynurenine in culture medium from human cancer cells.
Topics: Biosensing Techniques; Boron; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressu | 2020 |
Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Drug Design; Drug Scre | 2020 |
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2020 |
Kynurenine pathway enzyme KMO in cancer progression: A tip of the Iceberg.
Topics: Humans; Kynurenine; Neoplasms | 2020 |
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Female; | 2020 |
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Immune Tolerance; Immunotherapy; Indoleamine-Pyrrole 2,3 | 2020 |
Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Topics: Animals; Cell Line, Tumor; Dog Diseases; Dogs; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynuren | 2021 |
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem | 2017 |
Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.
Topics: Animals; Cell Line, Tumor; Imaging, Three-Dimensional; Kynurenine; Mass Spectrometry; Mice; Neoplasm | 2017 |
SBMLmod: a Python-based web application and web service for efficient data integration and model simulation.
Topics: Cell Line, Tumor; Humans; Internet; Kynurenine; Models, Theoretical; Neoplasms; Serotonin; Tryptopha | 2017 |
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Cell Line, Tumor; Humans; Hydrolases; Indoleamine- | 2018 |
Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
Topics: Animals; Biomarkers; Blood Chemical Analysis; Chromatography, Liquid; Indoleamine-Pyrrole 2,3,-Dioxy | 2018 |
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.
Topics: Administration, Oral; Alcohol Oxidoreductases; Animals; Autoimmune Diseases; Biopterins; Cell Line, | 2018 |
Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynur | 2019 |
Impact of physical exercise on the kynurenine pathway in patients with cancer: current limitations and future perspectives.
Topics: Depression; Depressive Disorder; Exercise; Humans; Kynurenine; Neoplasms | 2019 |
The landscape of cancer cell line metabolism.
Topics: Animals; Asparaginase; Asparagine; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Cell Lin | 2019 |
Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study.
Topics: Adult; Aged; Biomarkers, Tumor; C-Reactive Protein; Female; Follow-Up Studies; Humans; Inflammation; | 2014 |
Markers of vitamin B6 status and metabolism as predictors of incident cancer: the Hordaland Health Study.
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Health Surveys; Humans; Incidence; Kynurenine; Male; Mi | 2015 |
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Topics: Animals; Autocrine Communication; Cell Line, Tumor; Cytokines; Down-Regulation; Drug Resistance, Neo | 2015 |
Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.
Topics: DNA Replication; Genomic Instability; Glioma; Humans; Kynurenine; Neoplasms; Signal Transduction | 2016 |
Development of screen-printed tryptophan-kynurenine immunosensor for in vitro assay of kynurenine-mediated immunosuppression effect of cancer cells on activated T-cells.
Topics: Antibodies, Immobilized; Biosensing Techniques; Cell Line, Tumor; Electrodes; Equipment Design; Gold | 2017 |
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Topics: Amidines; Animals; Cell Line, Tumor; Dogs; Enzyme Inhibitors; Female; Humans; Immune System; Immunot | 2010 |
Indoleamine 2,3-dioxygenase, Tregs and cancer.
Topics: Animals; Enzyme Inhibitors; Forkhead Transcription Factors; Humans; Immune Tolerance; Indoleamine-Py | 2011 |
Evading immunity: new enzyme implicated in cancer.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2012 |
Kynurenine in disease, with particular reference to cancer.
Topics: Body Fluids; Kynurenine; Neoplasms; Urine | 1955 |
[Certain metabolic peculiarities observed in individuals with tumors of the bladder; preventive note].
Topics: Aminobenzoates; Humans; Kynurenine; Neoplasms; Urinary Bladder Neoplasms | 1958 |
Metabolism of tryptophan in cancer of various sites.
Topics: Indoleacetic Acids; Kynurenine; Neoplasms; ortho-Aminobenzoates; Tryptophan; Xanthurenates | 1963 |
PRELIMINARY STUDIES ON TRYPTOPHAN PYRROLASE ACTIVITY IN MICE.
Topics: Adenocarcinoma; Animals; Kynurenine; Liver; Mice; Neoplasms; Neoplasms, Experimental; Oxidation-Redu | 1963 |
[BIOCHEMICAL STUDIES ON THE METABOLISM OF THE TUMOR BEARING ANIMALS. II. RESEARCHES FOR THE AMINO ACIDS IN THE URINE OF THE RATS FED ON THE DAB-RICE].
Topics: Amino Acids; Chromatography; Kynurenine; Liver Neoplasms; Neoplasms; Neoplasms, Experimental; p-Dime | 1963 |
STUDIES ON THE TRYPTOPHAN METABOLISM IN TUMOR-BEARING ANIMALS.
Topics: Animals; Kynurenic Acid; Kynurenine; Liver; Neoplasms; Neoplasms, Experimental; Niacin; Nicotinic Ac | 1964 |
URINARY EXCRETION OF TRYPTOPHAN METABOLITES IN PATIENTS WITH RENAL PELVIS AND PARENCHYMA TUMOURS.
Topics: Chromatography; Humans; Kidney Neoplasms; Kidney Pelvis; Kynurenic Acid; Kynurenine; Neoplasms; orth | 1964 |
MOUSE BLADDER CARCINOGENICITY OF CERTAIN TRYPTOPHAN METABOLITES AND OTHER AROMATIC NITROGEN COMPOUNDS SUSPENDED IN CHOLESTEROL.
Topics: Amines; Animals; Carcinogens; Cholesterol; Fluorenes; Hydroxylamines; Kynurenic Acid; Kynurenine; Me | 1964 |
STUDIES ON THE URINARY EXCRETION OF CERTAIN TRYPTOPHAN METABOLITES BEFORE AND AFTER TRYPTOPHAN LOADING DOSE IN BILHARZIASIS, BILHARZIAL BLADDER CANCER AND CERTAIN OTHER TYPES OF MALIGNANCIES IN EGYPT.
Topics: Amino Acids; Egypt; Epidemiology; Fluids and Secretions; Humans; Hydroxyindoleacetic Acid; Indoleace | 1964 |
Kynurenine accumulation in tumor-bearing mice.
Topics: Animals; Kynurenine; Mice; Neoplasms | 1960 |
Diminished quality of life in patients with cancer correlates with tryptophan degradation.
Topics: Aged; Disease Progression; Fatigue; Female; Humans; Immunity, Cellular; Karnofsky Performance Status | 2007 |
Studies on tryptophan metabolism in malignant tumor.
Topics: Animals; Chromatography, Paper; Humans; Kynurenine; Mucoproteins; Neoplasms; Radiation Effects; Rats | 1967 |
Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis.
Topics: 3-Hydroxyanthranilic Acid; Animals; Bacterial Adhesion; Cyclamates; Glycosaminoglycans; Kynurenine; | 1987 |
Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Topics: Biopterins; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Interleukin-2; Kynurenine; Ne | 1989 |
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity.
Topics: Carcinoma; Cells, Cultured; Fibroblasts; Humans; Interferon beta-1a; Interferon beta-1b; Interferon | 1986 |
The tryptophan load as a test for pyridoxine deficiency in hospitalized patients.
Topics: Adult; Aged; Arteriosclerosis; Female; Gastrointestinal Diseases; Humans; Kynurenine; Male; Middle A | 1969 |
[Tryptophan-pyrrolase activity in patients with neoplasms of various types].
Topics: Humans; Kynurenine; Liver; Neoplasms; Tryptophan; Tryptophan Oxygenase | 1969 |